# Altesse Cosmetique Inc · 66-41 · CANADA — FDA import alert red lists: firms subject to detention without physical examination

For Altesse Cosmetique Inc · 66-41 · CANADA, import alert is 66-41; import alert name is Detention Without Physical Examination of Unapproved New Drugs Promoted In The U.S; country is CANADA; product code is 66 V - - 99 Miscellaneous Patent Medicines, Etc; date published is 09/30/2009; address is BP 452 BR , Montreal, QC CANADA, verified against its source on 2026-09-16.

- **Firm:** Altesse Cosmetique Inc _(verified: appears in the quote below)_
- **Import alert:** 66-41
- **Import alert name:** Detention Without Physical Examination of Unapproved New Drugs Promoted In The U.S.
- **Country:** CANADA _(verified: appears in the quote below)_
- **Address:** BP 452 BR , Montreal, QC CANADA _(verified: appears in the quote below)_
- **Date published:** 09/30/2009 _(verified: appears in the quote below)_
- **Product code:** 66 V - - 99 Miscellaneous Patent Medicines, Etc. _(verified: appears in the quote below)_
- **FDA notes:** Capillary Serum with Placenta. The buffalo district recently detained two hair lotions with claims of anti-hair loss. The district detained the products based on violation of 21 CFR 310.527(b) in that the products were represented as external hair loss prevention lotions which is regarded as a new drug within the meaning of section 201(p) for which a new drug application (NDA) under section 505 is required for marketing. The shipments were commercial entries which appeared to be for distribution and sale in the United States. _(verified: appears in the quote below)_

## What the source says

> Altesse Cosmetique Inc Date Published : 09/30/2009 BP 452 BR , Montreal, QC CANADA 66 V - - 99 Miscellaneous Patent Medicines, Etc. Date Published: 09/30/2009 Notes: Capillary Serum with Placenta. The buffalo district recently detained two hair lotions with claims of anti-hair loss. The district detained the products based on violation of 21 CFR 310.527(b) in that the products were represented as external hair loss prevention lotions which is regarded as a new drug within the meaning of section 201(p) for which a new drug application (NDA) under section 505 is required for marketing. The shipments were commercial entries which appeared to be for distribution and sale in the United States.

## Source

- https://www.accessdata.fda.gov/cms_ia/importalert_190.html

Last verified: 2026-09-16. Review by: 2026-11-15.
Part of [FDA import alert red lists: firms subject to detention without physical examination](https://referencesource.org/fda-import-alert-red-list/).